Tezepelumab did not significantly decrease moderate or severe COPD exacerbations compared with placebo, the COURSE trial found.

Elevated CAR has been associated with adverse outcomes in many conditions, including cancer, sepsis, COVID-19, and cardiovascular diseases. A higher C-reactive protein to albumin ratio (CAR) is ...

The pulmonary fibrosis market is driven by the increasing prevalence of pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF), among the aging population, which boosts demand for ...

In today’s fast-paced world, respiratory issues have become increasingly common, affecting individuals of all ages. Whether it’s due to environmental pollutants, allergens, or chronic conditions like ...

Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.8 billion, has been navigating a complex ...

We recently published a list of 10 Best Stocks to Buy and Hold For 2025. In this article, we are going to take a look at ...

For surgeons already split on their preference of inhaled pulmonary vasodilator to prevent postoperative right ventricular ...

Annual Meeting, researchers presented risk-adjusted findings that shed new light on treatments for severe emphysema.

If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations ...

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...

The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.

Certain Medicare plans typically cover at least part of the cost of inhalers for COPD. There are also several ways to further save on costs.